A novel STK1-targeted small-molecule as an "antibiotic resistance breaker" against multidrug-resistant Staphylococcus...

Area of Science:

• Microbiology
• Pharmacology
• Drug Discovery

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat due to antibiotic resistance.
• Serine/Threonine protein kinase (STK1) is crucial for MRSA cell wall biosynthesis and drug resistance.
• Existing antibiotics like Ceftriaxone and Cefotaxime are becoming less effective against MRSA.

Purpose of the Study:

• To identify and characterize a novel small molecule inhibitor of STK1.
• To evaluate the therapeutic potential of this inhibitor in combination with existing antibiotics against MRSA.
• To investigate the mechanism by which the inhibitor enhances antibiotic efficacy.

Main Methods:

• Synthesis and characterization of a novel quinazoline compound, Inh2-B1.
• In vitro assays to assess MRSA growth inhibition and STK1 activity.
• In vivo studies in mice to evaluate protection against MRSA challenge.
• Analysis of cell wall hydrolase gene expression and biofilm formation.

Main Results:

• Inh2-B1 specifically inhibits STK1 by binding to its ATP-binding catalytic domain.
• Inh2-B1 alone did not inhibit MRSA growth or protect mice at high concentrations.
• Combination of Inh2-B1 with Ceftriaxone or Cefotaxime significantly inhibited MRSA growth and protected mice.
• Inh2-B1 demonstrated low toxicity, down-regulated cell wall hydrolase genes, and disrupted MRSA biofilms.

Conclusions:

• Inh2-B1 acts as an "antibiotic-resistance-breaker" by inhibiting STK1.
• This novel compound enhances the bactericidal activity of cephalosporins against MRSA.
• Inh2-B1 represents a promising therapeutic agent for combination therapy against MRSA infections.